Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

Summary

The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma

Eligibility

Inclusion Criteria:

1. Newly-diagnosed histologically verified advanced stage (IIB-IV as per GHSG) classic Hodgkin lymphoma
2. No past history of autoimmune disease
3. Age \> 18 years
4. Ejection fraction \> 50%
5. ECOG 0-4

Exclusion Criteria:

1. Organ failure (e.g. creatinine \> 2x ULN; ALT or AST \> 5x ULN; bilirubin \> 2x ULN; hemodynamic instability; respiratory failure \> Grade 1)
2. Uncontrolled infection
3. Pregnancy
4. Inability to sign informed consent

Conditions2

Interventions4

Related trials

• A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India — Takeda
• Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE) — Swiss Cancer Institute
• First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) — State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
• A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab — National Cancer Institute (NCI)
• Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) — Advenchen Laboratories, LLC
• SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma — Immatics US, Inc.
• Brentuximab Vedotin in Early Stage Hodgkin Lymphoma — University College, London
• A Study of BV-AVD in People With Bulky Hodgkin Lymphoma — Memorial Sloan Kettering Cancer Center

Browse More Trials